 Nicholas Walter
Concepts (122)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Mycobacterium tuberculosis | 18 | 2025 | 307 | 5.720 |
Why?
| | Tuberculosis | 16 | 2025 | 271 | 5.130 |
Why?
| | Antitubercular Agents | 12 | 2025 | 199 | 3.370 |
Why?
| | Tuberculosis, Pulmonary | 7 | 2024 | 135 | 2.030 |
Why?
| | RNA, Ribosomal | 2 | 2021 | 162 | 1.400 |
Why?
| | Sputum | 7 | 2021 | 301 | 1.380 |
Why?
| | RNA, Bacterial | 4 | 2025 | 182 | 1.190 |
Why?
| | Anti-Bacterial Agents | 2 | 2025 | 1689 | 0.760 |
Why?
| | Mice, Inbred BALB C | 4 | 2025 | 1227 | 0.680 |
Why?
| | RNA Precursors | 1 | 2021 | 147 | 0.670 |
Why?
| | Polymerase Chain Reaction | 1 | 2022 | 1020 | 0.620 |
Why?
| | Transcriptome | 3 | 2025 | 879 | 0.620 |
Why?
| | Microbial Viability | 1 | 2018 | 82 | 0.580 |
Why?
| | Diarylquinolines | 3 | 2025 | 12 | 0.520 |
Why?
| | Disease Models, Animal | 5 | 2025 | 3936 | 0.520 |
Why?
| | Cell Membrane | 1 | 2018 | 725 | 0.460 |
Why?
| | Bronchoalveolar Lavage Fluid | 1 | 2016 | 624 | 0.430 |
Why?
| | Drug Therapy, Combination | 4 | 2025 | 1012 | 0.420 |
Why?
| | Energy Metabolism | 1 | 2018 | 831 | 0.400 |
Why?
| | Biomarkers | 3 | 2021 | 3874 | 0.380 |
Why?
| | Mice | 6 | 2025 | 16574 | 0.340 |
Why?
| | Gene Expression Regulation, Bacterial | 3 | 2023 | 322 | 0.320 |
Why?
| | Pyrazinamide | 2 | 2025 | 11 | 0.300 |
Why?
| | Gene Expression Profiling | 3 | 2023 | 1681 | 0.290 |
Why?
| | Linezolid | 2 | 2025 | 20 | 0.280 |
Why?
| | Communicable Disease Control | 1 | 2008 | 70 | 0.280 |
Why?
| | HIV Infections | 6 | 2020 | 2703 | 0.280 |
Why?
| | Anti-Infective Agents | 2 | 2023 | 243 | 0.250 |
Why?
| | Streptomycin | 1 | 2025 | 16 | 0.240 |
Why?
| | Animals | 6 | 2025 | 34487 | 0.240 |
Why?
| | Ethambutol | 1 | 2025 | 25 | 0.240 |
Why?
| | Protein Kinases | 2 | 2017 | 308 | 0.230 |
Why?
| | Isoniazid | 1 | 2025 | 61 | 0.230 |
Why?
| | Tuberculosis, Multidrug-Resistant | 1 | 2025 | 57 | 0.230 |
Why?
| | Rifampin | 1 | 2025 | 85 | 0.230 |
Why?
| | Transcription, Genetic | 2 | 2023 | 1403 | 0.220 |
Why?
| | Guideline Adherence | 1 | 2008 | 523 | 0.210 |
Why?
| | Mice, Inbred C3H | 1 | 2023 | 273 | 0.210 |
Why?
| | Mice, Inbred Strains | 1 | 2023 | 402 | 0.200 |
Why?
| | Adaptation, Physiological | 2 | 2023 | 513 | 0.190 |
Why?
| | Lung | 3 | 2024 | 3745 | 0.190 |
Why?
| | Coinfection | 3 | 2018 | 131 | 0.190 |
Why?
| | Bacterial Proteins | 2 | 2017 | 823 | 0.170 |
Why?
| | Ethanol | 1 | 2025 | 585 | 0.170 |
Why?
| | Female | 10 | 2025 | 68017 | 0.170 |
Why?
| | Uganda | 5 | 2020 | 72 | 0.170 |
Why?
| | Humans | 19 | 2025 | 128020 | 0.150 |
Why?
| | Phenotype | 2 | 2025 | 3039 | 0.150 |
Why?
| | Specimen Handling | 2 | 2016 | 163 | 0.140 |
Why?
| | RNA | 2 | 2014 | 881 | 0.140 |
Why?
| | AIDS-Related Opportunistic Infections | 2 | 2018 | 123 | 0.130 |
Why?
| | Anti-Retroviral Agents | 1 | 2018 | 230 | 0.130 |
Why?
| | Genes, Bacterial | 1 | 2016 | 158 | 0.130 |
Why?
| | Drug Monitoring | 1 | 2016 | 190 | 0.120 |
Why?
| | Microscopy | 2 | 2013 | 140 | 0.120 |
Why?
| | Adult | 7 | 2021 | 35177 | 0.120 |
Why?
| | Nitroimidazoles | 2 | 2025 | 9 | 0.120 |
Why?
| | Latent Tuberculosis | 1 | 2015 | 67 | 0.120 |
Why?
| | ROC Curve | 1 | 2015 | 500 | 0.110 |
Why?
| | Antigens, Fungal | 1 | 2013 | 27 | 0.110 |
Why?
| | Reagent Kits, Diagnostic | 1 | 2013 | 43 | 0.110 |
Why?
| | Mice, Inbred C57BL | 1 | 2023 | 5268 | 0.100 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2014 | 323 | 0.100 |
Why?
| | Cryptococcosis | 1 | 2013 | 25 | 0.100 |
Why?
| | Genome, Bacterial | 1 | 2014 | 134 | 0.100 |
Why?
| | Nystatin | 1 | 2012 | 1 | 0.100 |
Why?
| | Chlorhexidine | 1 | 2012 | 24 | 0.100 |
Why?
| | DNA-Binding Proteins | 2 | 2017 | 1421 | 0.100 |
Why?
| | Oxidative Stress | 1 | 2018 | 1181 | 0.100 |
Why?
| | Microbial Sensitivity Tests | 2 | 2024 | 348 | 0.100 |
Why?
| | HIV | 1 | 2012 | 225 | 0.090 |
Why?
| | Treatment Outcome | 2 | 2025 | 10110 | 0.090 |
Why?
| | Pneumonia | 1 | 2015 | 600 | 0.080 |
Why?
| | RNA, Messenger | 1 | 2016 | 2669 | 0.080 |
Why?
| | Case-Control Studies | 1 | 2015 | 3324 | 0.070 |
Why?
| | San Francisco | 1 | 2008 | 51 | 0.070 |
Why?
| | Emigration and Immigration | 1 | 2008 | 50 | 0.070 |
Why?
| | Male | 6 | 2021 | 62758 | 0.070 |
Why?
| | Inpatients | 2 | 2020 | 464 | 0.060 |
Why?
| | United States | 2 | 2015 | 13785 | 0.060 |
Why?
| | Oxazoles | 1 | 2025 | 30 | 0.060 |
Why?
| | Levofloxacin | 1 | 2025 | 25 | 0.060 |
Why?
| | Clofazimine | 1 | 2025 | 15 | 0.060 |
Why?
| | Clinical Trials, Phase II as Topic | 1 | 2025 | 72 | 0.060 |
Why?
| | Aged, 80 and over | 1 | 2015 | 7029 | 0.060 |
Why?
| | Multicenter Studies as Topic | 1 | 2025 | 285 | 0.050 |
Why?
| | Drug Administration Schedule | 1 | 2025 | 755 | 0.050 |
Why?
| | Sensitivity and Specificity | 2 | 2020 | 1813 | 0.050 |
Why?
| | Benchmarking | 1 | 2023 | 175 | 0.050 |
Why?
| | Young Adult | 1 | 2015 | 12282 | 0.040 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2025 | 1356 | 0.040 |
Why?
| | C-Reactive Protein | 1 | 2020 | 396 | 0.040 |
Why?
| | Middle Aged | 2 | 2018 | 30813 | 0.040 |
Why?
| | Gambia | 1 | 2017 | 14 | 0.030 |
Why?
| | Ghana | 1 | 2017 | 34 | 0.030 |
Why?
| | Molecular Epidemiology | 1 | 2017 | 63 | 0.030 |
Why?
| | Antiretroviral Therapy, Highly Active | 1 | 2018 | 265 | 0.030 |
Why?
| | Adolescent | 1 | 2015 | 20158 | 0.030 |
Why?
| | Aged | 1 | 2015 | 21892 | 0.030 |
Why?
| | World Health Organization | 1 | 2016 | 110 | 0.030 |
Why?
| | Prospective Studies | 2 | 2020 | 7035 | 0.030 |
Why?
| | Cryptococcus | 1 | 2013 | 7 | 0.030 |
Why?
| | Africa | 1 | 2013 | 98 | 0.030 |
Why?
| | Standard of Care | 1 | 2013 | 72 | 0.030 |
Why?
| | Mouthwashes | 1 | 2012 | 14 | 0.030 |
Why?
| | HIV-1 | 1 | 2018 | 833 | 0.020 |
Why?
| | Colony Count, Microbial | 1 | 2012 | 114 | 0.020 |
Why?
| | Diagnostic Tests, Routine | 1 | 2013 | 101 | 0.020 |
Why?
| | Oxygen | 1 | 2017 | 899 | 0.020 |
Why?
| | CD4 Lymphocyte Count | 1 | 2012 | 267 | 0.020 |
Why?
| | Genotype | 1 | 2017 | 1828 | 0.020 |
Why?
| | Survival Rate | 1 | 2016 | 1870 | 0.020 |
Why?
| | Single-Blind Method | 1 | 2012 | 267 | 0.020 |
Why?
| | Cough | 1 | 2012 | 115 | 0.020 |
Why?
| | Mortality | 1 | 2013 | 306 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2020 | 5034 | 0.020 |
Why?
| | Prevalence | 1 | 2016 | 2541 | 0.020 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2017 | 2059 | 0.020 |
Why?
| | Practice Guidelines as Topic | 1 | 2016 | 1482 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2016 | 2703 | 0.020 |
Why?
| | Incidence | 1 | 2013 | 2614 | 0.020 |
Why?
| | Time Factors | 1 | 2012 | 6479 | 0.010 |
Why?
|
|
Walter's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|